Published by Global Banking & Finance Review®
Posted on September 16, 2025
2 min readLast updated: January 21, 2026
Add as preferred source on GoogleUK must boost medicine investment, says minister, as pharma firms cut back. Industry criticizes UK's system for valuing medicines.
By Alistair Smout
LONDON (Reuters) -Britain needs to reverse its declining spend on medicines, science minister Patrick Vallance said on Tuesday, after two major pharmaceutical firms cancelled or paused investments and the industry warned of a difficult operating environment.
U.S. drugmaker Merck & Co, known as MSD in Europe, last week said it was scrapping research operations in London, while Reuters reported that AstraZeneca had paused a 200 million pound ($273 million) investment in Cambridge.
The pharmaceutical industry has been outspoken about what it says is Britain's underinvestment in life sciences, criticising its system for valuing medicines, known as NICE.
Its talks with the government over how much revenue from drug sales must be returned to the country's National Health Service have also stalled.
Vallance, who worked at GlaxoSmithKline before serving as Britain's Chief Scientific Adviser during the COVID pandemic, told a parliamentary committee hearing that appropriate access and payment for medicines was a "crunch issue" which "was causing an environment which the industry is finding difficult in the UK".
"I think there will be an increased percentage of NHS spend on medicines," he told lawmakers, adding he was "deeply concerned that there's been a 10-year decrease in the investment and support for a vital industry".
"The reason that I think we need to reverse that direction is not just price ... It's about saying we need to make sure that we get rapid uptake with the best new medicines."
On Tuesday, U.S. drugmaker Bristol Myers Squibb said that a "challenging access environment" in Britain had led it to halve the size of its local operation over the last four years.
Ben Lucas, VP Managing Director UK and Ireland at MSD, told the committee that the "commercial operating environment does need to be addressed", while AstraZeneca UK President Tom Keith-Roach said that the current dispute over drug pricing was a symptom rather than a cause of the problem.
"In the long term, this needs to be a country which is committed to investing in innovation, to making innovation available to patients and providing a front door through to the NHS through which innovative medicines can pass," he said.
($1 = 0.7324 pounds)
(Reporting by Alistair Smout. Additional reporting by Maggie Fick. Editing by Mark Potter)
Patrick Vallance stated that there needs to be an increased percentage of NHS spending on medicines, expressing concern over a 10-year decrease in investment.
U.S. drugmaker Merck & Co has scrapped research operations in London, and AstraZeneca has paused a £200 million investment.
The pharmaceutical industry has criticized the NICE system for undervaluing medicines, which they believe contributes to Britain's underinvestment in life sciences.
Bristol Myers Squibb reported that a challenging access environment in Britain has led it to halve the size of its local operation over the past four years.
The long-term vision includes a commitment to investing in innovation and ensuring that new medicines are made available to patients through the NHS.
Explore more articles in the Headlines category
